It is tempting to speculate that the effects seen in obstructive nephropathy can be extrapolated to other forms of chronic kidney diseases, making IL‐22 a potential therapeutical option to specifically target tubular epithelial cells. This evidence concerns the gene IL22 and chronic kidney disease.